Relmada Therapeutics, Inc.

Historical 13F Holders

Symbol
RLMD
CUSIP
75955J402
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 75955J402 since 12/18/2024, largest first.

Filer % of Class Filed
Janus Henderson Group PLC 13G 10.1% 2/6/2026
Event 1/30/2026
BlackRock, Inc. 13G 7.0% 7/29/2026
Event 6/30/2026
Squadron Capital Management LLC 13G/A
7.0% 8/14/2026
Event 6/30/2026
Venrock Healthcare Capital Partners III, L.P. 13G
6.2% 6/9/2026
Event 6/2/2026
Spruce Street Capital LP 13G
5.6% 2/17/2026
Event 12/31/2025
Commodore Capital LP 13G
5.1% 5/4/2026
Event 4/27/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Ikarian Capital, LLC 13G
4.8% 11/14/2025
Event 9/30/2025
Adage Capital Management, L.P. 13G/A
4.5% 5/13/2026
Event 3/31/2026
Millennium Management LLC 13G
4.4% 6/22/2026
Event 6/16/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 602 $2.27 k
2026 Q2 130 100 M $695 M
2026 Q1 109 85.3 M $593 M
2025 Q4 86 51.8 M $250 M
2025 Q3 46 7.74 M $15.5 M
2025 Q2 52 5.30 M $3.18 M
2025 Q1 45 6.22 M $1.68 M
2024 Q4 53 8.40 M $4.36 M
2024 Q3 78 12.7 M $41.3 M
2024 Q2 87 14.0 M $41.9 M
2024 Q1 102 14.7 M $68.5 M
2023 Q4 92 13.8 M $56.9 M
2023 Q3 93 15.0 M $45.0 M
2023 Q2 102 16.1 M $39.7 M
2023 Q1 96 17.8 M $40.3 M
2022 Q4 128 19.7 M $68.6 M
2022 Q3 174 25.8 M $955 M
2022 Q2 137 24.7 M $468 M
2022 Q1 135 23.1 M $623 M
2021 Q4 108 20.8 M $468 M
2021 Q3 94 10.0 M $263 M
2021 Q2 101 9.94 M $318 M
2021 Q1 93 9.54 M $336 M
2020 Q4 90 9.32 M $299 M
2020 Q3 81 10.4 M $393 M
2020 Q2 84 10.5 M $469 M
2020 Q1 46 9.36 M $319 M
2019 Q4 51 6.89 M $269 M
2019 Q3 1 0 $0